tiprankstipranks
Trending News
More News >
Electrocore Llc (ECOR)
NASDAQ:ECOR
US Market

Electrocore (ECOR) Earnings Dates, Call Summary & Reports

Compare
954 Followers

Earnings Data

Report Date
Apr 30, 2026
TBA (Confirmed)
Period Ending
2026 (Q1)
Consensus EPS Forecast
-0.6
Last Year’s EPS
-0.47
Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings

Earnings Call Summary

Q4 2025
Earnings Call Date:Mar 19, 2026|
% Change Since:
|
Earnings Call Sentiment|Neutral
The call highlighted strong top-line momentum — record Q4 revenue, double-digit annual growth (27% YoY), meaningful expansion in the general wellness channel (Truvaga +93% YoY) and early adoption in the VA/federal channel — along with strategic actions (leadership transition, experienced COO hire, Quell OTC launch) positioned to accelerate growth. Offsetting these positives are material operating cost increases, a wider GAAP net loss ($14.0M), modestly reduced cash balances (~$11.6M), nonrecurring other expenses, and limited near-term formal guidance due to the leadership transition. Overall, growth and commercial traction are clear, but profitability, expense control and liquidity remain important near-term challenges.
Company Guidance
Management said it sees full‑year 2026 revenue “potentially” growing ~30% year‑over‑year but, due to the leadership transition, is not providing detailed guidance now and will revisit formal guidance when appropriate; they expect the majority of 2026 revenue to continue coming from U.S. federal channels (VA). Management reiterated planned commercialization actions (new COO Michael Fox, expanded VA sales headcount) and a soft launch of Quell OTC in H1‑2026 — any Quell OTC revenue would be incremental to the ~30% outlook — and emphasized preserving operating discipline to move toward profitability. For context, they reported Q4‑2025 revenue of $9.2M (+31% YoY) and FY‑2025 revenue of $32.0M (+27% YoY), prescription revenue of ~$26M (+23% YoY) with Quell contributing $1.5M, approximately 13,400 VA patients on gammaCore (roughly 2% penetration) and facility coverage up from ~170 a year prior; FY‑2025 general wellness revenue was $5.5M (+97%) including Truvaga $5.4M (+93%), Q4 wellness $1.4M (+31%), ROAS ~ $2.10 (vs. $1.80 in Q3), adjusted EBITDA net loss of $8.7M and GAAP net loss of $14M in 2025.
Record Quarterly and Strong Annual Revenue Growth
Q4 2025 revenue reached a record $9.2 million, up 31% year-over-year; full year 2025 net sales were $32.0 million, up 27% versus 2024, and exceeded revenue and EPS analyst consensus.
Prescription Segment Growth (VA Focus)
Prescription revenue increased 23% year-over-year to $26 million driven by gammaCore and Quell adoption in the VA hospital system; approximately 13,400 VA patients have used gammaCore, representing roughly 2% penetration of the addressable VA headache market — indicating meaningful runway for expansion.
General Wellness Channel Expansion (Truvaga)
General wellness Q4 revenue was $1.4 million (+31% YoY) and full year general wellness revenue was $5.5 million, up 97% versus 2024. Truvaga sales were $5.4 million for the year, up 93% YoY, with increased direct-to-consumer traction, media endorsements, and retail placements (e.g., Best Buy).
Quell Acquisition Contributed Revenue
Following the Quell acquisition in May 2025, Quell-related revenue contributed $1.5 million to 2025 results and the company plans a Quell OTC (Quell Relief) launch in H1 2026 to further expand the product offering.
Improved Marketing Efficiency
Return on advertising spend (ROAS) improved to approximately $2.10 in the recent period versus $1.80 in Q3 2025. E-commerce conversion metrics remained around 12%–15% and excluding a one-time $0.5 million Truvaga clinical trial order, Truvaga grew ~40% sequentially.
Adjusted EBITDA Slightly Improved
Adjusted EBITDA net loss narrowed modestly to $(8.7) million for full year 2025 compared to $(9.0) million in 2024, reflecting incremental operational improvements after acquisition-related adjustments.
Leadership and Commercial Strengthening
CEO announced retirement effective April 1, 2026 with a planned transition (Joshua Lev as Interim President/CFO) and the hiring of Michael Fox as COO (experienced in federal/VA commercialization), designed to provide continuity and accelerate growth in the VA and federal channels.

Electrocore (ECOR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

ECOR Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Apr 30, 2026
2026 (Q1)
-0.59 / -
-0.47
Mar 19, 2026
2025 (Q4)
-0.40 / -0.34
-0.378.11% (+0.03)
Nov 05, 2025
2025 (Q3)
-0.40 / -0.40
-0.31-29.03% (-0.09)
Aug 06, 2025
2025 (Q2)
-0.33 / -0.44
-0.38-15.79% (-0.06)
May 07, 2025
2025 (Q1)
-0.48 / -0.47
-0.5311.32% (+0.06)
Mar 12, 2025
2024 (Q4)
-0.30 / -0.37
-0.6139.34% (+0.24)
Nov 13, 2024
2024 (Q3)
-0.33 / -0.31
-0.6854.41% (+0.37)
Aug 07, 2024
2024 (Q2)
-0.43 / -0.38
-1.0363.11% (+0.65)
May 08, 2024
2024 (Q1)
-0.59 / -0.53
-1.2457.26% (+0.71)
Mar 13, 2024
2023 (Q4)
-0.59 / -0.61
-1.2250.00% (+0.61)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

ECOR Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Mar 19, 2026
$6.55$6.25-4.65%
Nov 05, 2025
$4.74$5.84+23.21%
Aug 06, 2025
$6.93$4.91-29.15%
May 07, 2025
$6.81$5.19-23.79%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Electrocore Llc (ECOR) report earnings?
Electrocore Llc (ECOR) is schdueled to report earning on Apr 30, 2026, TBA (Confirmed).
    What is Electrocore Llc (ECOR) earnings time?
    Electrocore Llc (ECOR) earnings time is at Apr 30, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is ECOR EPS forecast?
          ECOR EPS forecast for the fiscal quarter 2026 (Q1) is -0.6.